Elan Drug Technologies – World's Leading Drug Delivery Business
Elan Drug Technologies, the world?s leading drug delivery business, develops and manufactures innovative pharmaceuticals using their extensive experience and proprietary drug technologies in partnership with pharmaceutical companies.
Elan Drug Technologies, the world’s leading drug delivery provider, is currently celebrating its’ 40th year in business as a fully integrated drug delivery provider. From NanoCrystal® technology for poorly water soluble compounds, to customised oral drug technologies, they offer clients drug delivery expertise with a suite of commercially launched, proprietary, technology-driven solutions. Since 2001, 12 products have been approved and launched in the US alone incorporating their technologies, making Elan Drug Technologies, in terms of product launches, the most successful drug delivery company of the decade. To date Elan’s drug delivery technologies have been commercialised in 36 products in more than 100 countries worldwide.
Strength in Numbers
40 years in drug delivery business
36 products marketed in 100+ countries
1,900+ patents/patent applications
14 products in clinical development
250,000 sq ft dedicated GMP manufacturing facilities
2.5 billion solid oral dosages can be manufactured annually
Over $20 billion in market sales generated for our licensees
They also have extensive product development, scale-up and manufacturing capabilities in the US and EU. Products enabled by them are used by millions of patients each day. More information is available at www.elandrugtechnologies.com
A Novel, Enhanced, and Sustainable Approach to Audit Trail Review
July 4th 2025Eli Lilly and Company developed an innovative and sustainable approach to audit trail review (ATR) aimed at reducing the ATR burden while adhering to regulatory expectations and data integrity (DI) principles. The process has transformed employees' understanding of ATR and complemented the DI by design approach, leading to better system designs that meet expected controls and reduce non-value-added data reviews.
Drug Solutions Podcast: Novel Drug Delivery Approaches: Refining AAV Vector Deliveries
May 30th 2025In this podcast episode, we discuss novel approaches to drug delivery, specifically regarding adeno-associated virus (AAV) vectors, as viewed by two industry experts who recently exhibited at the annual ASGCT meeting.
Transformations in Drug Development for Cell and Gene Therapies
March 28th 2025As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.
